A randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)
Clinical Trial Grant
Administered By
Neurology, Neuromuscular Disease
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 17, 2024
End Date
June 30, 2028
Administered By
Neurology, Neuromuscular Disease
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
June 17, 2024
End Date
June 30, 2028